) is set to report fourth quarter 2013 results on Jan 28 after
market close. Last quarter, the company had posted an earnings
surprise of +12.21%. Let's see how things are shaping up for this
Factors at Play
While products like Enbrel, Prolia, Xgeva, Neupogen and Neulasta
should continue performing well, Aranesp sales will remain under
pressure due to lower demand in the U.S. (resulting from dose
reductions) and in Europe due to competition and price cuts.
Meanwhile, results will be affected by higher operating costs
specially related to the promotion of Enbrel.
Our proven model does not conclusively show that Amgen is
likely to beat earnings this quarter. That is because a stock
needs to have both a positive
(Expected Surprise Prediction) and a Zacks Rank of #1, 2 or 3 for
this to happen. That is not the case here as you will see below.
Zacks Rank #3 (Hold):
The Earnings ESP for Amgen is 0.00% since the Most Accurate
Estimate stands at $1.64, in line with the Zacks Consensus
Amgen's Zacks Rank #3 (Hold) has little effect on the predictive
power of ESP because the Zacks Rank #3 when combined with a 0.00%
ESP makes surprise prediction difficult.
Other Stocks to Consider
Here are some other companies you may want to consider as our
model shows that they have the right combination of elements,
i.e., a positive Zacks Earnings ESP and a Zacks Rank #1, #2 or
) has an Earnings ESP of +0.33% and holds a Zacks Rank #2 (Buy).
Actavis will be reporting fourth quarter earnings on Feb 20.
Biogen Idec Inc.
) has an Earnings ESP of +9.01% and holds a Zacks Rank #2. Biogen
will be reporting fourth quarter earnings on Jan 29.
) has earnings ESP of +2.27% and holds a Zacks Rank #3. Sanofi
will report fourth quarter earnings on Feb 6.
ACTAVIS PLC (ACT): Free Stock Analysis Report
AMGEN INC (AMGN): Free Stock Analysis Report
BIOGEN IDEC INC (BIIB): Free Stock Analysis
SANOFI-AVENTIS (SNY): Free Stock Analysis
To read this article on Zacks.com click here.